89336-46-9

Basic information

• Product Name: (2-TERT-BUTOXYCARBONYLAMINO-THIAZOL-4-YL)-ACETIC ACID
• Synonyms: (2-TERT-BUTOXYCARBONYLAMINO-THIAZOL-4-YL)-ACETIC ACID;BOC-2-AMINO-4-THIAZOLE ACETIC ACID;N-BOC-2-amino-4-thiazolacetic acid;2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetic acid;4-Thiazoleacetic acid, 2-[[(1,1-dimethylethoxy)carbonyl]amino;(2-TERT-BUTOXYCARBONYLAMINO-THIAZOL-4-YL)-ACETIC AC
• CAS NO: 89336-46-9
• Molecular Formula: C₁₀H₁₄N₂O₄S
• Molecular Weight: 258.29
• Mol File: 89336-46-9.mol
• Article Data: 10

Chemical Properties

• Melting Point: 168 °C
• Appearance: /
• Density: 1.37 g/cm³
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 5.20±0.70(Predicted)
• CAS DataBase Reference: (2-TERT-BUTOXYCARBONYLAMINO-THIAZOL-4-YL)-ACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: (2-TERT-BUTOXYCARBONYLAMINO-THIAZOL-4-YL)-ACETIC ACID(89336-46-9)
• EPA Substance Registry System: (2-TERT-BUTOXYCARBONYLAMINO-THIAZOL-4-YL)-ACETIC ACID(89336-46-9)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 89336-46-9(Hazardous Substances Data)

Usage

Uses

Boc-2-amino-4-thiazole Acetic Acid is a reactant that is used in the preparation of phenylhydroxylmethylpyrrolidinylmetylphenylthiozolylacetaimde deriivatives as human β3 adrenergic receptor agonists via multi step synthesis.

Upstream product

• 53266-94-7 ethyl 2-amino-1,3-thiazol-4-acetate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 29676-71-9 2-amino-4-thiazoleacetic acid 
• 82548-78-5 ethyl {2-[(tert-butoxycarbonyl)amino]-1,3-thiazol-4-yl}acetate 
• 64987-16-2 (2-amino-thiazol-4-yl)-acetic acid methyl ester 
• 103053-96-9 methyl 2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetate 

Downstream Products

• 140128-58-1 (6R,7R)-7-[2-(2-tert-Butoxycarbonylamino-thiazol-4-yl)-acetylamino]-8-oxo-3-(1-trityl-1H-[1,2,3]triazol-4-ylsulfanylmethylsulfanyl)-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid benzhydryl ester 
• 223673-61-8 (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetanilide 
• 1345689-74-8 C₆₀H₆₄ClN₆O₁₁S₂⁽¹⁺⁾*I^(1-) 
• 1190387-69-9 2-(2-amino-1,3-thiazol-4-yl)-N-[4-({(2S,5R)-[(R)-hydroxy(phenyl)methyl]pyrrolidinyl}methyl)phenyl]acetamide 
• 1314024-48-0 C₃₃H₄₂N₄O₆S 
• 1190615-39-4 tert-butyl (2S,5R)-2-{4-[({2-[(tert-butoxycarbonyl)amino]-1,3-thiazol-4-yl}acetyl)amino]benzyl}-5-[(R)-{[tert-butyl(dimethyl)silyl]oxy}(pyridin-3-yl)methyl]pyrrolidine-1-carboxylate trifluoroacetate 

Relevant articles and documents

A Novel Minor Groove Binder as a Potential Therapeutic Agent for Myotonic Dystrophy Type 1

Myotonic dystrophy type 1 (DM1) is a multisystemic neuromuscular disorder that is inherited in an autosomal dominant manner. DM1 originates in a (CTG?CAG) repeat expansion in the 3’-UTR of the dystrophia myotonic protein kinase (DMPK) gene on chromosome 19. One of the transcripts, r(CUG)exp, is toxic in various ways. Herein we report a rationally designed small molecule with a thiazole peptidomimetic unit that can serve as a minor groove binder for the nucleic acid targets. This peptide unit linked to two triaminotriazine recognition units selectively binds to d(CTG)exp to inhibit the transcription process, and also targets r(CUG)exp selectively to improve representative DM1 pathological molecular features, including foci formation and pre-mRNA splicing defects in DM1 model cells. As such, it represents a new structure type that might serve as a lead compound for future structure-activity optimization.

Target-Directed Azide-Alkyne Cycloaddition for Assembling HIV-1 TAR RNA Binding Ligands

The highly conserved HIV-1 transactivation response element (TAR) binds to the trans-activator protein Tat and facilitates viral replication in its latent state. The inhibition of Tat–TAR interactions by selectively targeting TAR RNA has been used as a strategy to develop potent antiviral agents. Therefore, HIV-1 TAR RNA represents a paradigmatic system for therapeutic intervention. Herein, we have employed biotin-tagged TAR RNA to assemble its own ligands from a pool of reactive azide and alkyne building blocks. To identify the binding sites and selectivity of the ligands, the in situ cycloaddition has been further performed using control nucleotide (TAR DNA and TAR RNA without bulge) templates. The hit triazole-linked thiazole peptidomimetic products have been isolated from the biotin-tagged target templates using streptavidin beads. The major triazole lead generated by the TAR RNA presumably binds in the bulge region, shows specificity for TAR RNA over TAR DNA, and inhibits Tat–TAR interactions.

Synthesizing method of {2-[2-(2-amino-4-thiazolyl)-amino acetyl]-4-thiazolyl}-acetic acid

The invention discloses a synthesizing method of {2-[2-(2-amino-4-thiazolyl)-amino acetyl]-4-thiazolyl}-acetic acid, belongs to the technical field of medicine synthesis, and provides a new synthesizing method of {2-[2-(2-amino-4-thiazolyl)-amino acetyl]-4-thiazolyl}-acetic acid. The synthesizing method comprises the following synthesizing steps of (1) esterification reaction: reacting (2-Aminothiazole-4-yl)acetic acid and ethanol into ester, so as to obtain an intermediate product A; (2) amino protection: reacting (2-Aminothiazole-4-yl)acetic acid and t-butyloxycarboryl, so as to generate an intermediate product B; (3) amide condensation reaction: condensing the intermediate product A and the intermediate product B by a condensing agent, so as to generate an intermediate product C; (4) deprotection reaction: removing ester and t-butyloxycarboryl from the intermediate product C by trifluoroacetic acid, so as to obtain a target product. The synthesizing method has the advantages that the cost is low, the yield rate of the product is high, and the synthesizing method is suitable for large-scale industrial production.